NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Shattuck Labs, Inc. (STTK) Stock Analysis

Shattuck Labs, Inc. (STTK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

STTK

$6.79

−$0.17 (−2.44%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STTK with… →

STTK Key Statistics

As of Sep 4, 2026
Trading
Open
$6.84
Previous Close
$6.96
Day's Range
6.67–6.88
52-Week Range
1.59–8.33
Volume
677.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$681.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
681.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.44
Financials (FY)
Revenue (FY)
$1.00M−82.52%
Net Income (FY)
−$48.81M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.36M
1-Year Return
+349.67%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STTK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+86.03%
2025+201.65%
2024−83.03%
2023+210.00%
2022−72.97%
2021−83.76%
2020 (partial year)+170.85%

As of September 4, 2026.

STTK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.00M−$48.81M−4880.9%
2024$5.72M−$75.41M−1318.1%
2023$1.66M−$87.30M−5268.4%
2022$652.00K−$101.95M−15635.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.00M—−$51.51M−$48.81M−4880.9%
2024$5.72M—−$80.57M−$75.41M−1318.1%
2023$1.66M—−$91.96M−$87.30M−5268.4%
2022$652.00K—−$103.33M−$101.95M−15635.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STTK Valuation vs Biotechnology Median

Median of 656 stocks
MetricSTTKBiotechnology medianvs median
P/S ratio681.4715.2644.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Shattuck Labs, Inc. (STTK) at $681.47M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 40.

The most recent close on file for STTK is $6.79, dated September 4, 2026. That is −$0.17 (−2.44%) against the previous close. The 52-week range on file runs from $1.59 to $8.33. The latest close sits 327.04% above that 52-week low.

Financial Health

In fiscal 2025, Shattuck Labs, Inc. reported revenue of $1.00M. Against the prior fiscal year total of $5.72M, that is a change of −82.52%. The same year closed with a net loss of $48.81M. The reported profit margin is 0%. Trailing earnings per share are −0.44.

Across the 4 fiscal years on file, revenue moves from $652.00K in 2022 to $1.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 681.47. On price-to-sales that is 44.6 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.1. Annualized volatility over the trailing 5 years is 118.44%. Over the trailing twelve months the price has returned +349.67%. Measured over 5 years, that is −20.42% a year compounded.

Growth & Income

The record shows no dividend for STTK.

2026 is still running; the price is +86.03% year to date. The strongest complete calendar year on file is 2023 at +210.00%; the weakest is 2021 at −83.76%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Shattuck Labs, Inc. (STTK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Shattuck Labs, Inc. STTK $681.47M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Shattuck Labs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Visit website →